NUVISAN and Bayer Create New Research Unit in Berlin

Published on: 

Applied Clinical Trials

NUVISAN has agreed with Bayer to integrate large parts of Bayer’s Berlin-based small molecule research unit and complements hereby its services in the field of preclinical research. The strategic partnership will lay the foundation for a new research entity to be established by the two companies. The transaction is expected to close mid 2020.

For more information, click here.